LLY is a health care giant, creating medicines for diabetes, oncology, immunology, neuroscience, and obesity, along with using advanced technologies and AI to make more treatments. The company’s second-quarter fiscal 2026 earnings report, LLY showed $23 billion in quarterly revenue (a 48% year-over-year gain) led by its Zepbound and Mounjaro products ($14.9 billion together), non-GAAP per-share earnings of $8.38 (a 32.8% annual jump), and offered annual guidance of up to $87 billion and $36.50 for revenue and EPS, respectively. The company reports again on Oct. 29.
It’s no wonder LLY shares are up 19% this year, and they could rise more. MoneyFlows data shows how Big Money investors are betting heavily on the stock.
Institutions Buying Eli Lilly
Institutional volumes reveal plenty. In the last year, LLY has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in LLY shares. They reflect our proprietary inflow signal, pushing the stock higher:
Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Eli Lilly.
Eli Lilly Fundamental Analysis
Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, LLY has had strong sales and earnings growth:
- 3-year sales growth rate (+32.1%)
- 3-year EPS growth rate (+60.6%)
Source: FactSet
Also, EPS is estimated to ramp higher this year by +39.9%.
Now it makes sense why the stock has been generating Big Money interest. LLY has a track record of strong financial performance.
Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.
Eli Lilly has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
Since 1990, LLY has drawn 103 outlier inflow signals and is up 19,899%. The blue bars below show when LLY was a top pick on the Outlier 20 report in the last year…institutions keep buying:
Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
Eli Lilly Price Prediction
The LLY action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.
Disclosure: the author holds no position in LLY at the time of publication.
If you are a Registered Investment Advisor (RIA) or a serious investor, take your investing to the next level. MoneyFlows created 11 Frontiers indexes to help serious investors capture AI-driven themes and learn the leading stocks in each Frontier. Get started here.